Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 15/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL420556 | 1.00 | AMY1A (0.67) | AMY1AKMT2AMEN1L3MBTL1GAA | |
| SCHEMBL28967919 | 0.85 | KMT2A (0.90) | AMY1AKMT2AMEN1L3MBTL1GAA | |
| SCHEMBL28967914 | 0.85 | KMT2A (0.90) | AMY1AKMT2AMEN1L3MBTL1GAA | |
| SCHEMBL28468357 | 0.83 | KMT2A (0.79) | AMY1AKMT2AMEN1L3MBTL1GAA | |
| SCHEMBL419809 | 0.81 | AMY1A (0.68) | AMY1AKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL446086 | 0.81 | AMY1A (0.68) | AMY1AKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL443451 | 0.80 | KMT2A (1.00) | AMY1AKMT2AMEN1L3MBTL1GAA | |
| SCHEMBL418912 | 0.80 | KMT2A (1.00) | AMY1AKMT2AMEN1L3MBTL1GAA | |
| SCHEMBL419549 | 0.80 | KMT2A (0.67) | AMY1AKMT2AMEN1L3MBTL1GAA | |
| SCHEMBL447476 | 0.80 | KMT2A (0.67) | AMY1AKMT2AMEN1L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335517-A1 | DETECTION AND TREATMENT OF SCHIZOPHRENIA | RENASCIENCE CO LTD (JP) | 2014-11-13 | — | — | US | disclosed |
| US-8809329-B2 | Detection and treatment of schizophrenia | TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (JP) | 2014-08-19 | — | — | US | disclosed |
| EP-2662453-A2 | Detection and treatment of schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2013-11-13 | — | — | EP | disclosed |
| US-20120065198-A2 | Detection and Treatment of Schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20110028470-A1 | Detection and Treatment of Schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2189537-A1 | DETECTION AND TREATMENT OF SCHIZOPHRENIA | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2010-05-26 | — | — | EP | disclosed |
| US-7645882-B2 | Inhibitor of protein modification products formation | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20070123577-A1 | Inhibitor of protein modification products formation | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2007-05-31 | — | — | US | disclosed |
| EP-1693369-A1 | PROTEIN MODIFIER PRODUCTION INHIBITOR | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2006-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123577-A1 | Inhibitor of protein modification products formation | SERPINB6, PROC, PLPBP | AMY1A 1685/4885KMT2A 2334/4885MEN1 1277/4885 |
| US-20110028470-A1 | Detection and Treatment of Schizophrenia | GLO1, CBR1, AOX1 | AMY1A 1713/4885KMT2A 1703/4885MEN1 4818/4885 |
| US-20120065198-A2 | Detection and Treatment of Schizophrenia | GLO1, CBR1, AOX1 | AMY1A 1713/4885KMT2A 1703/4885MEN1 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.